Literature DB >> 1324634

Pharmacokinetics and tissue penetration of ampicillin and brobactam following oral administration of 2085P.

R Wise1, N O'Sullivan, J Johnson, J M Andrews.   

Abstract

Eight healthy volunteers received a 1,000-mg single oral dose of 2085P which consisted of 800 mg of pivampicillin and 200 mg of brobactam. Concentrations of ampicillin and brobactam in plasma, inflammatory fluid, and urine were measured over the subsequent 24 h. Pivampicillin and brobactam were moderately rapidly absorbed. The mean (standard deviation) maximum concentration in plasma (Cmax) of ampicillin was 8.2 (1.9) micrograms/ml, and that of brobactam was 2.1 (2.0) micrograms/ml at mean times of 1.9 (0.5) and 2.3 (0.8) h, respectively. The elimination half-lives in plasma were 1.8 (0.5) and 1.6 (2.0) h, respectively. Both agents penetrated the experimentally induced inflammatory fluid, reaching a mean maximum at 3 h. The Cmax of ampicillin was 6.8 (2.3) micrograms/ml, and that of brobactam was 1.0 (0.4) micrograms/ml. The penetration (derived by comparing the area under the concentration-time curve from 0 h to infinity for inflammatory fluid with that for plasma) was 97.3% (26.0%) for ampicillin and 81% (22.3%) for brobactam. The 24-h urinary recovery was 54.2% (16.6%) of the administered dose for ampicillin and 40.2% (11.4%) for brobactam. These data suggest that this combination of beta-lactam and inhibitor should be efficacious in treating infections caused by ampicillin-resistant pathogens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324634      PMCID: PMC188825          DOI: 10.1128/AAC.36.5.1002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Triple crossover study on absorption and excretion of ampicillin, pivampicillin, and amoxycillin.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  In-vitro evaluation of ampicillin/brobactam and comparison with other beta-lactam antibiotics.

Authors:  N H Melchior; J Keiding
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

3.  Studies on the absorption of pivampicillin and ampicillin.

Authors:  E R Hultberg; B Backelin
Journal:  Scand J Infect Dis       Date:  1972

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Penicillins and cephalosporins: antimicrobial and pharmacological properties.

Authors:  R Wise
Journal:  Lancet       Date:  1982-07-17       Impact factor: 79.321

6.  6-beta-bromo- and 6-beta-iodo penicillanic acid, two novel beta-lactamase inhibitors.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

  6 in total
  4 in total

1.  A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326).

Authors:  R Wise; J M Andrews; L Da Ros; J Child; D Mortiboy
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

Authors:  R Sutherland
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

3.  Structural basis of the inhibition of class A beta-lactamases and penicillin-binding proteins by 6-beta-iodopenicillanate.

Authors:  Eric Sauvage; Astrid Zervosen; Georges Dive; Raphael Herman; Ana Amoroso; Bernard Joris; Eveline Fonzé; Rex F Pratt; André Luxen; Paulette Charlier; Frédéric Kerff
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

Review 4.  Antibiotic resistance breakers: current approaches and future directions.

Authors:  Mark Laws; Ali Shaaban; Khondaker Miraz Rahman
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.